How much funding has Avitide raised?

Avitide has raised $11.0M in total funding, most recently a series c round.

Who are Avitide's investors?

Avitide's investors include Borealis Ventures, NeoMed Management, Polaris Venture Partners, OrbiMed, SV Life Sciences.

Where is Avitide headquartered?

Avitide is headquartered in Lebanon, New Hampshire, United States.

What industry is Avitide in?

Avitide operates in Biotech, Life Sciences.

Avitide

Acquired

A new generation of purification technologies for biopharmaceutical manufacturing.

Lebanon, United States · Founded 2013 · $11.0M raised

Biotech

Life Sciences

Headquarters: Lebanon, New Hampshire
Employees: 11–50
Founded: 2013
Business Model: B2B

Website: avitide.com
Total Funding: $11.0M
Last Round: $7.6M Series CAug 2015
Rounds: 3

About

Avitide is the industry's premier biopharmaceutical affinity purification partner. The company develops a proprietary portfolio of AVIPure™ affinity ligands and end-to-end purification platforms for novel drug modalities including gene therapies, viral vaccines, bispecific antibodies, and cell-based therapies. Avitide works with partners from concept through commercial resin supply, delivering improved purity, yield, and manufacturing economics—reducing cost of goods and accelerating development timelines for biologic manufacturers. Acquired by Repligen in 2021.

Summary

Avitide is a Biotech company based in Lebanon, United States, founded in 2013. It has raised $11.0M in total across 3 rounds, most recently a $7.6M Series C round in Aug 2015. Investors include Borealis Ventures, NeoMed Management and Polaris Venture Partners.